` CRBU (Caribou Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

CRBU
vs
S&P 500

Over the past 12 months, CRBU has underperformed S&P 500, delivering a return of -26% compared to the S&P 500's 9% growth.

Stocks Performance
CRBU vs S&P 500

Loading
CRBU
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CRBU vs S&P 500

Loading
CRBU
S&P 500
Difference
www.alphaspread.com

Performance By Year
CRBU vs S&P 500

Loading
CRBU
S&P 500
Add Stock

Competitors Performance
Caribou Biosciences Inc vs Peers

S&P 500
CRBU
ABBV
AMGN
GILD
VRTX
Add Stock

Caribou Biosciences Inc
Glance View

Market Cap
119m USD
Industry
Biotechnology

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.

CRBU Intrinsic Value
2.11 USD
Undervaluation 39%
Intrinsic Value
Price
Back to Top